EE148 Canadian Cost-Effectiveness Analysis of Deferiprone Compared to Deferoxamine and Deferasirox for the Treatment of Iron Overload in Patients With Sickle Cell Disease and Other Anemias
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.400
https://www.valueinhealthjournal.com/article/S1098-3015(22)02604-3/fulltext
Title :
EE148 Canadian Cost-Effectiveness Analysis of Deferiprone Compared to Deferoxamine and Deferasirox for the Treatment of Iron Overload in Patients With Sickle Cell Disease and Other Anemias
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02604-3&doi=10.1016/j.jval.2022.09.400
First page :
Section Title :
Open access? :
No
Section Order :
12210